Shandong Boan Biotechnology (HKG:6955) said its novel CD228-directed antibody-drug conjugate (ADC), BA1302, received Orphan Drug Designation (ODD) from the Food and Drug Administration (FDA) for the treatment of squamous non-small cell lung cancer (sqNSCLC) and pancreatic cancer, according to a Wednesday filing with the Hong Kong bourse.
BA1302 targets CD228, a protein overexpressed in multiple tumors, to inhibit cancer cell migration and proliferation while minimizing off-target toxicity.
The biopharmaceutical company's shares were up 2% in recent trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。